|
WO1999032120A1
(en)
*
|
1997-12-22 |
1999-07-01 |
Euro-Celtique, S.A. |
A method of preventing abuse of opioid dosage forms
|
|
UA55507C2
(uk)
|
1997-12-22 |
2003-04-15 |
Еро-Селтік, С.А. |
Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
EP2295043A1
(en)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
EP2517710B1
(en)
*
|
2000-02-08 |
2015-03-25 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
|
EP2932964A1
(en)
|
2000-10-30 |
2015-10-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
US7858118B2
(en)
*
|
2001-04-11 |
2010-12-28 |
Galephar Pharmaceutical Research, Inc. |
Extended release composition containing Tramadol
|
|
WO2002092059A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
|
CN1525851A
(zh)
*
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
|
WO2003002100A1
(en)
*
|
2001-06-26 |
2003-01-09 |
Farrell John J |
Tamper-proof narcotic delivery system
|
|
JP2005515966A
(ja)
*
|
2001-07-06 |
2005-06-02 |
エンドー ファーマシューティカルズ， インコーポレイティド |
鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
|
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
|
DE60223254T2
(de)
*
|
2001-07-06 |
2008-08-14 |
Penwest Pharmaceuticals Co. |
Verzögert freisetzende formulierungen von oxymorphon
|
|
IL159917A0
(en)
*
|
2001-07-18 |
2004-06-20 |
Euro Celtique Sa |
Pharmaceutical combinations of oxycodone and naloxone
|
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
|
US7332182B2
(en)
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
|
US7144587B2
(en)
*
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
|
JP4504013B2
(ja)
*
|
2001-08-06 |
2010-07-14 |
ユーロ−セルティーク エス．エイ． |
放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
|
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US20030049317A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Lindsay David R. |
Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
|
|
JP2005523876A
(ja)
*
|
2001-09-26 |
2005-08-11 |
ペンウェスト ファーマシューティカルズ カンパニー |
乱用の可能性が低減したオピオイド製剤
|
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
DK2939696T3
(en)
|
2001-10-18 |
2016-05-23 |
Nektar Therapeutics |
Polymer Conjugates of Opioid Antagonists
|
|
WO2003039561A1
(en)
*
|
2001-11-02 |
2003-05-15 |
Elan Corporation, Plc |
Pharmaceutical composition
|
|
US20060177381A1
(en)
*
|
2002-02-15 |
2006-08-10 |
Howard Brooks-Korn |
Opiopathies
|
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
|
EP2319540A1
(en)
*
|
2002-02-22 |
2011-05-11 |
Shire LLC |
Sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
|
EP2289492B1
(en)
*
|
2002-03-14 |
2016-12-07 |
Euro-Celtique S.A. |
Naltrexone hydrochloride compositions
|
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
|
GB0206505D0
(en)
*
|
2002-03-19 |
2002-05-01 |
Euro Celtique Sa |
Pharmaceutical combination
|
|
ATE432065T1
(de)
*
|
2002-03-26 |
2009-06-15 |
Euro Celtique Sa |
Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
|
|
DK2425821T5
(en)
|
2002-04-05 |
2018-02-12 |
Mundipharma As |
Pharmaceutical preparation containing oxycodone and naloxone
|
|
CA2480824A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
|
PT1492511E
(pt)
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
|
CA2496454A1
(en)
|
2002-04-23 |
2003-11-06 |
Alza Corporation |
Transdermal analgesic systems with reduced abuse potential
|
|
US20040156844A1
(en)
*
|
2002-05-22 |
2004-08-12 |
Curtis Wright |
Tamper resistant oral dosage form
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
US8557291B2
(en)
*
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
|
WO2004004693A1
(en)
|
2002-07-05 |
2004-01-15 |
Collgegium Pharmaceutical |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US8840928B2
(en)
*
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
AU2003281182A1
(en)
*
|
2002-07-11 |
2004-02-02 |
Taiho Pharmaceutical Co., Ltd. |
Composition for nasal absorption
|
|
MY142204A
(en)
|
2002-07-25 |
2010-10-29 |
Pharmacia Corp |
Pramipexole once-daily dosage form
|
|
DE10237056A1
(de)
*
|
2002-08-09 |
2004-03-04 |
Grünenthal GmbH |
Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
|
|
CN1674873A
(zh)
*
|
2002-08-15 |
2005-09-28 |
欧罗赛铁克股份有限公司 |
药物组合物
|
|
HUE038446T2
(hu)
*
|
2002-09-20 |
2018-10-29 |
Alpharma Pharmaceuticals Llc |
Szekvesztráló alegység és releváns kompozíciók és módszerek
|
|
WO2004026256A2
(en)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sustained-release opioid formulations and methods of use
|
|
CA2499994C
(en)
*
|
2002-09-23 |
2012-07-10 |
Verion, Inc. |
Abuse-resistant pharmaceutical compositions
|
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
EP1555996A2
(en)
|
2002-10-31 |
2005-07-27 |
Euro-Celtique |
Pharmaceutical identification
|
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
|
US7524515B2
(en)
*
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
|
DE10305137A1
(de)
*
|
2003-02-07 |
2004-08-26 |
Novosis Ag |
Transdermale therapeutische Abgabesysteme mit einem Butenolid
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
WO2004093819A2
(en)
|
2003-04-21 |
2004-11-04 |
Euro-Celtique, S.A. |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
|
TWI347201B
(en)
*
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
|
MXPA05011557A
(es)
|
2003-04-29 |
2006-03-09 |
Orexigen Therapeutics Inc |
Composiciones para afectar perdida de peso.
|
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
ME00276B
(me)
*
|
2003-04-30 |
2011-05-10 |
Purdue Pharma Lp |
Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
|
|
EP2112920B1
(en)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
PT1658054E
(pt)
*
|
2003-08-06 |
2007-09-18 |
Gruenenthal Gmbh |
''forma de dosagem que está salvaguardada de abuso''
|
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
PL1663229T3
(pl)
*
|
2003-09-25 |
2010-09-30 |
Euro Celtique Sa |
Farmaceutyczne kombinacje hydrokodonu i naltreksonu
|
|
DK1663229T3
(da)
*
|
2003-09-25 |
2010-08-09 |
Euro Celtique Sa |
Farmaceutiske kombinationer af hydrocodon og naltrexon
|
|
AU2004281153A1
(en)
*
|
2003-10-15 |
2005-04-28 |
Pain Therapeutics, Inc. |
Treatment of arthritic conditions, chronic inflammation or pain
|
|
US20050245557A1
(en)
*
|
2003-10-15 |
2005-11-03 |
Pain Therapeutics, Inc. |
Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
|
|
KR20060120678A
(ko)
|
2003-10-30 |
2006-11-27 |
알자 코포레이션 |
남용될 가능성이 감소된 경피용 진통제 시스템
|
|
JP4917893B2
(ja)
*
|
2003-12-09 |
2012-04-18 |
ユーロ−セルティーク エス．エイ． |
作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
|
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
|
TWI350762B
(en)
*
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
|
WO2006079550A2
(en)
*
|
2005-01-28 |
2006-08-03 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
|
LT2351555T
(lt)
*
|
2004-02-23 |
2016-12-27 |
Euro-Celtique S.A. |
Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
|
|
TWI365880B
(en)
*
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
|
WO2005097075A2
(en)
|
2004-03-30 |
2005-10-20 |
Euro-Celtique S.A. |
Tamper resistant dosage form comprising an adsorbent and an adverse agent
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
LT1765292T
(lt)
|
2004-06-12 |
2018-01-10 |
Collegium Pharmaceutical, Inc. |
Nuo piktnaudžiavimo apsaugotos vaistų formos
|
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
BRPI0513848A
(pt)
*
|
2004-08-13 |
2008-05-20 |
Boehringer Ingelheim Int |
formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
GB2418854B
(en)
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
FR2881652B1
(fr)
*
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
FR2889810A1
(fr)
*
|
2005-05-24 |
2007-02-23 |
Flamel Technologies Sa |
Forme medicamenteuse orale, microparticulaire, anti-mesurage
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
WO2006124890A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Alpharma, Inc. |
Morphine sulphate formulations
|
|
US20080193537A1
(en)
*
|
2005-05-13 |
2008-08-14 |
Alpharma, Inc. |
Morphine Sulfate Formulations
|
|
WO2006124584A2
(en)
|
2005-05-13 |
2006-11-23 |
Alza Corporation |
Multilayer drug delivery system with barrier against reservoir material flow
|
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
|
WO2006133733A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
|
CA2617164A1
(en)
*
|
2005-08-01 |
2007-02-08 |
Alpharma Inc. |
Alcohol resistant pharmaceutical formulations
|
|
CA2617681C
(en)
|
2005-08-02 |
2015-02-03 |
Sol-Gel Technologies Ltd. |
Metal oxide coating of water insoluble ingredients
|
|
US9125833B2
(en)
*
|
2005-11-02 |
2015-09-08 |
Relmada Therapeutics, Inc. |
Multimodal abuse resistant and extended release opioid formulations
|
|
US8329744B2
(en)
*
|
2005-11-02 |
2012-12-11 |
Relmada Therapeutics, Inc. |
Methods of preventing the serotonin syndrome and compositions for use thereof
|
|
WO2007087452A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Theraquest Biosciences, Llc |
Abuse resistant and extended release formulations and method of use thereof
|
|
US8652529B2
(en)
*
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
|
EP2135603B1
(en)
|
2005-11-22 |
2013-01-02 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
|
EP1968539A2
(en)
*
|
2005-12-13 |
2008-09-17 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
EP1810678A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
|
EP1810714A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
|
|
MX2008009267A
(es)
*
|
2006-01-21 |
2008-10-09 |
Abbott Gmbh & Co Kg |
Forma farmaceutica y metodo para la administracion de farmacos de abuso.
|
|
US20070185145A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Royds Robert B |
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
|
|
US7939567B2
(en)
*
|
2006-02-24 |
2011-05-10 |
Blue Blood Biotech Corp. |
Dextromethorphan-based method for treating acne
|
|
FR2898056B1
(fr)
*
|
2006-03-01 |
2012-01-20 |
Ethypharm Sa |
Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
|
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
|
KR101495146B1
(ko)
|
2006-03-16 |
2015-02-24 |
트리스 파마 인코포레이티드 |
약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
|
|
GB0606124D0
(en)
*
|
2006-03-28 |
2006-05-03 |
Reckitt Benckiser Healthcare |
Buprenorphine derivatives and uses thereof
|
|
CA2648280C
(en)
*
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
|
EP2019586A4
(en)
*
|
2006-05-03 |
2009-09-02 |
Proethic Pharmaceuticals Inc |
MEDICATION OF ACUTE PAIN BASED ON FAST DICLOFENAC OPIOID COMBINATIONS
|
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
EP2484346B1
(en)
|
2006-06-19 |
2017-02-22 |
Alpharma Pharmaceuticals LLC |
Pharmaceutical compositions
|
|
US8765178B2
(en)
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
|
AU2011205222B2
(en)
*
|
2006-07-21 |
2014-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
EP2049087A2
(en)
*
|
2006-07-21 |
2009-04-22 |
LAB International SRL |
Hydrophilic abuse deterrent delivery system
|
|
RU2504377C2
(ru)
*
|
2006-07-21 |
2014-01-20 |
БайоДеливери Сайенсиз Интэнэшнл, Инк. |
Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
|
WO2008027442A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Theraquest Biosciences, Llc |
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
|
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
|
US8187636B2
(en)
*
|
2006-09-25 |
2012-05-29 |
Atlantic Pharmaceuticals, Inc. |
Dosage forms for tamper prone therapeutic agents
|
|
JP2010506833A
(ja)
*
|
2006-10-11 |
2010-03-04 |
アルファーマ，インコーポレイテッド |
医薬組成物
|
|
JP2010508997A
(ja)
|
2006-11-09 |
2010-03-25 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
減量薬を投与するための方法
|
|
DE102006054731B4
(de)
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
|
|
EP2101740B1
(en)
|
2006-12-04 |
2013-11-06 |
Orexo AB |
New non-abusable pharmaceutical composition comprising opioids
|
|
KR20090125243A
(ko)
|
2007-02-01 |
2009-12-04 |
솔-겔 테크놀로지스 리미티드 |
퍼옥사이드 및 레티노이드를 함유하는 국소 도포용 조성물
|
|
AU2008211554B2
(en)
|
2007-02-01 |
2013-12-19 |
Sol-Gel Technologies Ltd. |
Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
|
|
GB2447014A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
|
WO2008109462A2
(en)
|
2007-03-02 |
2008-09-12 |
Farnam Companies, Inc. |
Sustained release pellets comprising wax-like material
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
|
AU2008286914B2
(en)
|
2007-08-13 |
2014-10-02 |
Ohemo Life Sciences Inc. |
Abuse resistant drugs, method of use and method of making
|
|
EP3064198A1
(en)
*
|
2007-09-03 |
2016-09-07 |
Nanotherapeutics, Inc. |
Particulate compositions for delivery of poorly soluble drugs
|
|
CA2709992A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Abuse resistant pharmaceutical compositions of opiod agonists
|
|
WO2009079518A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals. Llc |
Pharmaceutical composition
|
|
RU2010129907A
(ru)
|
2007-12-17 |
2012-01-27 |
Лабофарм Инк. (CA) |
Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
|
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
CA2709950A1
(en)
*
|
2007-12-17 |
2009-07-09 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
CA2709905A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alfred Liang |
Abuse-resistant oxycodone composition
|
|
RU2493830C2
(ru)
|
2008-01-25 |
2013-09-27 |
Грюненталь Гмбх |
Лекарственная форма
|
|
US9700552B2
(en)
|
2008-02-28 |
2017-07-11 |
Syntropharma Limited |
Pharmaceutical compositions for treatment of addiction
|
|
LT2273983T
(lt)
|
2008-05-09 |
2016-10-25 |
Grünenthal GmbH |
Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
|
|
MX2010012909A
(es)
|
2008-05-30 |
2011-02-25 |
Orexigen Therapeutics Inc |
Metodos para tratamiento de condiciones de grasa visceral.
|
|
RU2478388C2
(ru)
*
|
2008-07-07 |
2013-04-10 |
Еуро-Селтик С.А. |
Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
|
|
US20100099696A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Anthony Edward Soscia |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
MX2011004455A
(es)
*
|
2008-10-30 |
2011-05-25 |
Gruenenthal Gmbh |
Formas de dosificacion del tapentadol novedosas y potentes.
|
|
ES2414856T3
(es)
*
|
2008-12-12 |
2013-07-23 |
Paladin Labs Inc. |
Formulaciones de fármaco narcótico con potencial de adicción disminuido
|
|
US8486449B2
(en)
*
|
2008-12-16 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
|
AU2009332963B2
(en)
|
2008-12-31 |
2015-02-05 |
Upsher-Smith Laboratories, Llc |
Opioid-containing oral pharmaceutical compositions and methods
|
|
EP2448406B1
(en)
*
|
2009-02-26 |
2016-04-20 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
|
AR075735A1
(es)
|
2009-03-10 |
2011-04-20 |
Euro Celtique Sa |
Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
|
|
US20120040009A1
(en)
*
|
2009-04-22 |
2012-02-16 |
Lars Holger Hermann |
Particulate pharmaceutical composition with an opioid and an opioid antagonist
|
|
GB0909680D0
(en)
|
2009-06-05 |
2009-07-22 |
Euro Celtique Sa |
Dosage form
|
|
RU2567723C2
(ru)
|
2009-07-22 |
2015-11-10 |
Грюненталь Гмбх |
Стабильная при окислении, прочная на излом лекарственная форма
|
|
JP5667183B2
(ja)
|
2009-07-22 |
2015-02-12 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
加熱溶融押出成型した制御放出性投与剤型
|
|
AU2009352681B2
(en)
|
2009-09-17 |
2014-11-20 |
Upsher-Smith Laboratories, Llc |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
CA2785822C
(en)
|
2010-01-11 |
2019-06-25 |
Orexigen Therapeutics, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
|
EP2531176B1
(en)
|
2010-02-03 |
2016-09-07 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
|
US20120321716A1
(en)
|
2011-02-17 |
2012-12-20 |
Michael Vachon |
Technology for preventing abuse of solid dosage forms
|
|
CA2792878C
(en)
|
2010-03-12 |
2019-10-22 |
Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services |
Agonist/antagonist compositions and methods of use
|
|
MX347105B
(es)
*
|
2010-05-10 |
2017-04-12 |
Euro Celtique Sa |
Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
|
|
CA2798885C
(en)
*
|
2010-05-10 |
2014-11-18 |
Euro-Celtique S.A. |
Combination of active loaded granules with additional actives
|
|
CA2798884C
(en)
|
2010-05-10 |
2016-09-13 |
Euro-Celtique S.A. |
Manufacturing of active-free granules and tablets comprising the same
|
|
JP2013526523A
(ja)
|
2010-05-11 |
2013-06-24 |
シマ ラブス インク． |
メトプロロールを含むアルコール耐性持続放出性経口剤形
|
|
CA2808541C
(en)
|
2010-09-02 |
2019-01-08 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising an anionic polymer
|
|
EP2611426B1
(en)
|
2010-09-02 |
2014-06-25 |
Grünenthal GmbH |
Tamper resistant dosage form comprising inorganic salt
|
|
DE102010048883A1
(de)
|
2010-10-19 |
2012-04-19 |
Lars Holger Hermann |
Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
|
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
|
JP2012087101A
(ja)
*
|
2010-10-21 |
2012-05-10 |
Holger Hermann Lars |
オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
|
|
AP3815A
(en)
|
2010-12-22 |
2016-09-30 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
|
PH12013501345A1
(en)
|
2010-12-23 |
2022-10-24 |
Purdue Pharma Lp |
Tamper resistant solid oral dosage forms
|
|
MY162895A
(en)
*
|
2010-12-28 |
2017-07-31 |
Euro Celtique Sa |
A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
|
|
CN102068697B
(zh)
*
|
2010-12-30 |
2013-10-16 |
宜昌人福药业有限责任公司 |
含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
|
|
AU2012213056A1
(en)
|
2011-02-02 |
2013-07-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition comprising opioid agonist and sequestered antagonist
|
|
US20140127300A1
(en)
*
|
2011-06-30 |
2014-05-08 |
Neos Therapeutics, Lp |
Abuse resistant drug forms
|
|
US20130028972A1
(en)
|
2011-07-29 |
2013-01-31 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
|
JP2014524925A
(ja)
|
2011-07-29 |
2014-09-25 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時薬剤放出を提供するタンパーレジスタント錠剤
|
|
SG11201401446RA
(en)
|
2011-08-18 |
2014-09-26 |
Biodelivery Sciences Int Inc |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
|
MX361757B
(es)
|
2011-09-19 |
2018-12-13 |
Orexo Ab |
Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
|
|
JP6144274B2
(ja)
*
|
2011-12-09 |
2017-06-07 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ポリ（イプシロン−カプロラクトン）およびポリエチレンオキシドを含む医薬剤形
|
|
AR089201A1
(es)
|
2011-12-12 |
2014-08-06 |
Lohmann Therapie Syst Lts |
Sistema de suministro transdermico
|
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
UA118540C2
(uk)
*
|
2011-12-21 |
2019-02-11 |
Біоделівері Сайєнсиз Інтернешнл, Інк. |
Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю
|
|
JP6117249B2
(ja)
|
2012-02-28 |
2017-04-19 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
|
|
US9687445B2
(en)
*
|
2012-04-12 |
2017-06-27 |
Lts Lohmann Therapie-Systeme Ag |
Oral film containing opiate enteric-release beads
|
|
EP2844236B1
(en)
|
2012-04-17 |
2018-12-19 |
Purdue Pharma LP |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
CA2868142A1
(en)
|
2012-04-18 |
2013-10-24 |
Grunenthal Gmbh |
Tamper resistant and dose-dumping resistant pharmaceutical dosage form
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
US8802658B2
(en)
|
2012-05-14 |
2014-08-12 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US10028908B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9949993B2
(en)
|
2012-05-14 |
2018-04-24 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US10463682B2
(en)
|
2012-05-14 |
2019-11-05 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
|
|
US9925203B2
(en)
|
2012-05-14 |
2018-03-27 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9655908B2
(en)
|
2012-05-14 |
2017-05-23 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US9844559B2
(en)
|
2012-05-14 |
2017-12-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesions
|
|
US10493085B2
(en)
|
2012-05-14 |
2019-12-03 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US9943531B2
(en)
|
2014-08-08 |
2018-04-17 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9662343B2
(en)
|
2012-05-14 |
2017-05-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9789128B2
(en)
|
2012-05-14 |
2017-10-17 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9867839B2
(en)
|
2012-05-14 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US9827256B2
(en)
|
2014-05-27 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating lower back pain
|
|
US9616078B2
(en)
|
2012-05-14 |
2017-04-11 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US10350227B2
(en)
|
2012-05-14 |
2019-07-16 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10039773B2
(en)
|
2012-05-14 |
2018-08-07 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating arthritis
|
|
US9694023B2
(en)
|
2012-05-14 |
2017-07-04 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US10016446B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
|
|
US8865757B1
(en)
|
2014-05-28 |
2014-10-21 |
Antecip Bioventures Ii Llp |
Therapeutic compositions comprising imidazole and imidazolium compounds
|
|
US9717747B2
(en)
|
2012-05-14 |
2017-08-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10413561B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US10080765B2
(en)
|
2012-05-14 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9861648B2
(en)
|
2012-05-14 |
2018-01-09 |
Antecip Boiventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10028969B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9707247B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US10413560B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9211257B2
(en)
|
2012-05-14 |
2015-12-15 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9669040B2
(en)
|
2012-05-14 |
2017-06-06 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9867840B2
(en)
|
2014-05-27 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9901589B2
(en)
|
2012-05-14 |
2018-02-27 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9795622B2
(en)
|
2012-05-14 |
2017-10-24 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating pain associated with a joint
|
|
US9675626B2
(en)
|
2012-05-14 |
2017-06-13 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9820999B2
(en)
|
2012-05-14 |
2017-11-21 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9782421B1
(en)
|
2012-05-14 |
2017-10-10 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US9895383B2
(en)
|
2012-05-14 |
2018-02-20 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9770457B2
(en)
|
2012-05-14 |
2017-09-26 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesion
|
|
US9707245B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10016445B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956237B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9956234B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US9427403B2
(en)
|
2012-05-14 |
2016-08-30 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9877977B2
(en)
|
2012-05-14 |
2018-01-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10092581B2
(en)
|
2014-05-15 |
2018-10-09 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9700570B2
(en)
|
2014-05-27 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9827192B2
(en)
|
2012-05-14 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9289441B2
(en)
|
2014-08-08 |
2016-03-22 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US10004756B2
(en)
|
2014-05-15 |
2018-06-26 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10034890B2
(en)
|
2012-05-14 |
2018-07-31 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10111837B2
(en)
|
2012-05-14 |
2018-10-30 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds
|
|
US9999629B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10173986B2
(en)
|
2012-05-14 |
2019-01-08 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9956238B2
(en)
|
2014-05-15 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9999628B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US11654152B2
(en)
|
2012-05-14 |
2023-05-23 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
KR20200035501A
(ko)
|
2012-06-06 |
2020-04-03 |
오렉시젠 세러퓨틱스 인크. |
과체중 및 비만의 치료 방법
|
|
WO2014011830A1
(en)
|
2012-07-12 |
2014-01-16 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
|
US9687465B2
(en)
|
2012-11-27 |
2017-06-27 |
Sol-Gel Technologies Ltd. |
Compositions for the treatment of rosacea
|
|
KR101659983B1
(ko)
*
|
2012-12-31 |
2016-09-26 |
주식회사 삼양바이오팜 |
용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
|
|
PE20151301A1
(es)
|
2013-02-05 |
2015-09-16 |
Purdue Pharma Lp |
Formulaciones farmaceuticas resistentes a la manipulacion indebida
|
|
WO2014146093A2
(en)
|
2013-03-15 |
2014-09-18 |
Inspirion Delivery Technologies, Llc |
Abuse deterrent compositions and methods of use
|
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
|
JP6445537B2
(ja)
*
|
2013-05-29 |
2018-12-26 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
|
|
CA2913209A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper resistant dosage form with bimodal release profile
|
|
LT2810646T
(lt)
|
2013-06-04 |
2016-10-25 |
Lts Lohmann Therapie-Systeme Ag |
Transderminė tiekimo sistema
|
|
BR112016000194A8
(pt)
|
2013-07-12 |
2019-12-31 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
|
|
WO2015011189A1
(en)
|
2013-07-23 |
2015-01-29 |
Euro-Celtique S.A. |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
WO2015065546A2
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Abuse-deterrent dosage forms
|
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
|
EP3068397A1
(en)
|
2013-11-13 |
2016-09-21 |
Euro-Celtique S.A. |
Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
|
|
BR112016010482B1
(pt)
|
2013-11-26 |
2022-11-16 |
Grünenthal GmbH |
Preparação de uma composição farmacêutica em pó por meio de criomoagem
|
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
|
EP3116478A1
(en)
|
2014-03-14 |
2017-01-18 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US10085937B2
(en)
|
2014-03-14 |
2018-10-02 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
US9480644B2
(en)
|
2014-03-14 |
2016-11-01 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US9561177B2
(en)
|
2014-03-14 |
2017-02-07 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
JP2017518980A
(ja)
|
2014-05-12 |
2017-07-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
タペンタドールを含む、改変防止即時放出カプセル製剤
|
|
JP2017516789A
(ja)
|
2014-05-26 |
2017-06-22 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エタノール過量放出に対して防護されている多粒子
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
|
US10493027B2
(en)
|
2014-08-07 |
2019-12-03 |
Mucodel Pharma Llc |
Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
|
|
WO2016022816A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Mucodel Pharma Llc |
Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
EP3229785A2
(de)
*
|
2014-12-08 |
2017-10-18 |
Develco Pharma Schweiz AG |
Naloxon-monopräparat und mehrschichttablette
|
|
EP3229788A4
(en)
|
2014-12-08 |
2018-06-13 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
FR3032353B1
(fr)
|
2015-02-06 |
2017-03-10 |
Jacques Seguin |
Composition pharmaceutique et dispositif pour le traitement de la douleur
|
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
EP3344997B1
(en)
*
|
2015-08-31 |
2020-11-18 |
Regents of the University of Minnesota |
Opioid receptor modulators and use thereof
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
AU2016319782A1
(en)
*
|
2015-09-09 |
2018-04-05 |
Micell Technologies, Inc. |
Biopharma application of micell technology
|
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
|
US9861629B1
(en)
|
2015-10-07 |
2018-01-09 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
|
GB201520390D0
(en)
*
|
2015-11-19 |
2016-01-06 |
Euro Celtique Sa |
Composition
|
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
|
CA2972220C
(en)
|
2016-06-29 |
2023-01-24 |
Disposerx, Inc. |
Disposal of medicaments
|
|
WO2018012627A1
(ja)
*
|
2016-07-15 |
2018-01-18 |
シャープ株式会社 |
送風装置および空気調和機
|
|
WO2018208241A1
(en)
*
|
2017-05-10 |
2018-11-15 |
İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi |
Formulation and optimization of controlled release tablets of morphine sulphate
|
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
|
CA3068036A1
(en)
|
2017-06-30 |
2019-01-03 |
Purdue Pharma L.P. |
Use to buprenorphine in combination with an opioid to treat pain
|
|
RS67243B1
(sr)
|
2017-07-12 |
2025-10-31 |
Sol Gel Tech Ltd |
Supstance koje obuhvataju tretinoin u kapsulama
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
AU2018347991A1
(en)
*
|
2017-10-09 |
2020-05-07 |
Rhodes Pharmaceuticals L.P. |
Pharmaceutical resinate compositions and methods of making and using thereof
|
|
EP3473246A1
(en)
|
2017-10-19 |
2019-04-24 |
Capsugel Belgium NV |
Immediate release abuse deterrent formulations
|
|
WO2019079729A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Purdue Pharma L.P. |
PHARMACEUTICAL DOSAGE FORMS
|
|
EP3727384A4
(en)
|
2017-12-20 |
2021-11-03 |
Purdue Pharma L.P. |
ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
|
|
US10624856B2
(en)
|
2018-01-31 |
2020-04-21 |
Dharma Laboratories LLC |
Non-extractable oral solid dosage forms
|
|
CN109232748B
(zh)
*
|
2018-09-26 |
2019-06-11 |
哈尔滨工业大学 |
多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
|
|
WO2020159901A1
(en)
*
|
2019-01-31 |
2020-08-06 |
Relmada Therapeutics, Inc. |
Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
WO2020225773A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
AU2020309829A1
(en)
*
|
2019-07-10 |
2022-01-20 |
Intas Pharmaceuticals Ltd. |
Naltrexone formulation
|
|
IT201900013473A1
(it)
*
|
2019-07-31 |
2021-01-31 |
Vetagro Int S R L |
Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
|
|
EP3936112A1
(en)
*
|
2020-07-07 |
2022-01-12 |
Occlugel |
Hydrophilic degradable microspheres for delivering buprenorphine
|
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
|
KR20240135842A
(ko)
*
|
2022-01-26 |
2024-09-12 |
알드바크 테라퓨틱스 인크. |
자폐증-관련 장애를 치료하기 위한 액체 수지 연장-방출 경구 날트렉손 제제
|
|
US12303604B1
(en)
|
2024-10-16 |
2025-05-20 |
Currax Pharmaceuticals Llc |
Pharmaceutical formulations comprising naltrexone and/or bupropion
|